Hi Butcherano, I would say use that TOTAL 40% or greater reduction in Proteinuria as a guide for a clinically meaningful benefit, but the 2 trials are different in both design & drug/s obviously.
Ann: Application for quotation of securities - DXB, page-114
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.3¢ |
Change
0.008(1.69%) |
Mkt cap ! $239.5M | |||
| Open | High | Low | Value | Volume |
| 44.5¢ | 45.3¢ | 43.0¢ | $174.1K | 396.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1168 | 45.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 149763 | 8 |
View Market Depth
| Last trade - 12.27pm 20/08/2024 (20 minute delay) ? |
| DXB (ASX) Chart |